Cargando…
Pulmonary Delivery of Favipiravir in Rats Reaches High Local Concentrations without Causing Oxidative Lung Injury or Systemic Side Effects
Favipiravir displays a rapid viral clearance, a high recovery rate and broad therapeutic safety; however, its oral administration was associated with systemic side effects in susceptible patients. Considering that the pulmonary route could provide a high drug concentration, and a safer application w...
Autores principales: | Akbal-Dagistan, Ozlem, Sevim, Mustafa, Sen, Leyla Semiha, Basarir, Nur Sena, Culha, Meltem, Erturk, Aybige, Fael, Hanan, Kaptan, Engin, Sancar, Serap, Mulazimoglu Durmusoglu, Lutfiye, Yegen, Berrak C., Yildiz-Pekoz, Ayca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9696372/ https://www.ncbi.nlm.nih.gov/pubmed/36365193 http://dx.doi.org/10.3390/pharmaceutics14112375 |
Ejemplares similares
-
Pulmonary delivery of favipiravir inhalation solution for COVID-19 treatment: in vitro characterization, stability, in vitro cytotoxicity, and antiviral activity using real time cell analysis
por: Yildiz Pekoz, Ayca, et al.
Publicado: (2022) -
Antivirals and the Potential Benefits of Orally Inhaled Drug Administration in COVID-19 Treatment
por: Sahin, Gokben, et al.
Publicado: (2022) -
Early Effects of Low Molecular Weight Heparin Therapy with Soft-Mist Inhaler for COVID-19-Induced Hypoxemia: A Phase IIb Trial
por: Erelel, Mustafa, et al.
Publicado: (2021) -
A new scoring system for early diagnosis of ventilator-associated pneumonia: LUPPIS
por: Haliloglu, Murat, et al.
Publicado: (2020) -
Advances in Pulmonary Drug Delivery
por: Yıldız-Peköz, Ayca, et al.
Publicado: (2020)